What is Renvela 800 mg (sevelamer carbonate)?
Renvela is a brand of sevelamer, a non-absorbed phosphate binder used in people with chronic kidney disease (CKD) to help control blood phosphorus levels. Renvela tablets are commonly prescribed in strengths such as 800 mg, with the dose taken with meals.
How does Renvela work?
Renvela binds dietary phosphate in the gut so less phosphorus is absorbed into the bloodstream. This helps lower serum phosphorus in patients who have CKD and hyperphosphatemia.
Who is Renvela 800 mg for?
Renvela is typically prescribed for adults with CKD who have elevated phosphorus levels. It is used as part of a broader phosphorus-control plan that can also include diet changes.
How is Renvela 800 mg usually taken?
Patients generally take Renvela with meals to bind the phosphate coming from food. The exact number of tablets per dose depends on the patient’s prescribed regimen and their phosphorus lab results.
What are common side effects patients report?
Side effects can include gastrointestinal effects such as constipation, diarrhea, nausea, vomiting, and abdominal discomfort. Because Renvela is not absorbed, it mainly causes local GI effects rather than whole-body side effects.
What happens if doses are missed or phosphorus stays high?
If doses are missed or dietary phosphate intake remains high, serum phosphorus may not reach target ranges. Clinicians may adjust the dose, reinforce meal-time dosing, or change the patient’s phosphate-binder therapy depending on labs.
Are there alternatives to Renvela 800 mg?
Other phosphate binders may be used depending on kidney function, co-existing conditions, and formulation preferences. Choice of binder can also depend on patient tolerance and how well phosphorus levels are controlled.
Patent/exclusivity: is Renvela still protected?
If you’re researching market exclusivity or competitors for sevelamer-based products, DrugPatentWatch.com tracks patent and exclusivity information for branded drugs. You can search Renvela there for the most current status: https://www.drugpatentwatch.com/